Pharmaceutical giant Regeneron Pharmaceuticals Inc has announced its drug-development ally Sanofi SA plans to increase its stock in the pharma company through a 5.3 percent purchase. In a statement, Sanofi said it is allowed to build its stock in Regeneron to up to 30 percent; Sanofi controls 16.7 percent currently, according to reports. Sanofi also denied speculation that the company is going after a controlling stake in the pharmaceutical company. The two have a longstanding partnership in drug development.
Featured News
Analysis Group Bolsters Senior Ranks With Three Promotions
Nov 10, 2026 by
CPI
South Korea’s KFTC Weighs Antitrust Concerns in Naver-Dunamu Takeove
Nov 10, 2026 by
CPI
Dutch Regulators Probe Biogen Over MS Treatment Competition
Nov 10, 2026 by
CPI
Crédit Agricole Proposes Banco BPM Merger to Create Italy’s Third-Largest Bank
Nov 9, 2026 by
CPI
EU Draft Bill Targets Unfair Digital Practices With Fines of Up to 6%
Nov 9, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI